Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT03370198
NCT03370198TerminatedPhase 1

An Open-label Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer

Celyad Oncology SA2 sites in 1 country1 target enrollmentStarted: October 11, 2017Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Status
Terminated
Enrollment
1
Locations
2
Primary Endpoint
The occurrence of DLTs until 14 days after the last NKR-2 study treatment administration (Visit Day 43)
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The purpose of this study is to test an experimental anti-cancer immunotherapy called NKR-2 (modified T cells), to treat colorectal cancer with unresectable liver metastases. The trial will test three dose levels (dose escalation). At each dose, the patients will receive three successive hepatic transarterial administrations, two weeks apart, of NKR-2 cells. The study will enroll up to 18 patients.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Sequential
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •The patient must be ≥ 18 years old at the time of signing the ICF.
  • •The patient must have a histologically proven adenocarcinoma of the colon or rectum.
  • •The patient must have liver metastases non treatable with curative intent by surgical resection or local ablation at the time of registration.
  • •The patient must have measurable hepatic metastases defined by RECIST version 1.1 for solid tumors.
  • •The patient must have received one prior chemotherapy line for metastatic disease and have developed resistance or intolerance to this treatment.
  • •The patient must have an ECOG performance status 0 or
  • •The patient must have the bone marrow reserve, hepatic and renal functions

Exclusion Criteria

  • •Patients who are presenting evidence of ascites, cirrhosis, portal hypertension, main portal venous tumor involvement or thrombosis as determined by clinical or radiologic assessment.
  • •Patients who are planned to receive or concurrently receiving any non-cancer-directed investigational agent, or have received a non-cancer directed investigational agent within 3 weeks before the planned day for the first NKR-2 administration.
  • •Patients who are scheduled to receive concurrent growth factor (except erythropoietin), systemic steroid, other immunosuppressive therapy or cytotoxic agents (systemic or localized) other than the treatment authorized per protocol.
  • •Patients who underwent major surgery within 4 weeks before the planned day for the first NKR-2 administration.
  • •Patients who have received a live vaccine ≤ 6 weeks prior to the planned day for the first NKR-2 administration.
  • •Patients with a family history of congenital or hereditary immunodeficiency.
  • •Patients with history of any autoimmune disease.

Outcomes

Primary Outcomes

The occurrence of DLTs until 14 days after the last NKR-2 study treatment administration (Visit Day 43)

Time Frame: From study treatment start (Day 1) till 14 days after the last NKR-2 study treatment administration (Day 43)

A DLT is defined as any Grade 3 or higher toxicity and any Grade 2 or higher autoimmune toxicity

Secondary Outcomes

  • The occurrence and duration of clinical benefit (complete response (CR), partial response (PR) and stable disease (SD))(through study completion (up to month 24))
  • The occurrence of AEs and SAEs during the study treatment until 30 days after the last study treatment administration (Visit Day 57)(From study treatment start (Day 1) till 30 days after the last study treatment administration (Day 57))
  • The progression-free survival (PFS)(through study completion (up to month 24))
  • The event-free survival (EFS)(through study completion (up to month 24))
  • The occurrence and duration of objective clinical response (complete response (CR), partial response (PR))(through study completion (up to month 24))
  • The resection rate at Visits Day 57 and Month 3(At visits Day 57 and Month 3)
  • The overall survival (OS).(through study completion (up to month 24))
  • The occurrence and duration of mixed response (MR)(through study completion (up to month 24))

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials

Completed
Phase 1
Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional TherapyPathologically Confirmed Cancer Refractory to Conventional TherapyRefractory CancerMetastatic CancerRecurrent CancerSolid Tumor, AdultSolid TumorAdvanced CancerAdvanced Solid Tumor
NCT05990920NKGen Biotech, Inc.6
Terminated
Phase 1
A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin LymphomaClassical Hodgkin LymphomaNon-Hodgkin Lymphoma
NCT06018129Genmab9
Recruiting
Phase 1
Safety and Efficacy of KLS-1 Monotherapy in Malignant NeoplasmsSolid Tumor, AdultCLL
NCT06506643Vector Vitale LLC36
Completed
Phase 1
Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular CarcinomaCarcinoma, Hepatocellular
NCT01594125Boehringer Ingelheim30
Unknown
Phase 1
A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer IndicationsAcute Myeloid Leukemia/Myelodysplastic SyndromeMultiple Myeloma (MM)
NCT03018405Celyad Oncology SA146
Hepatic Transarterial Administrations of... | Clinical Trial